Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD34+ stem cell boost
- Development stage
- Preclinical
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
An autologous CD34+ stem cell boost is a cellular therapy procedure involving the reinfusion of a patient's own previously collected and cryopreserved CD34+ hematopoietic stem and progenitor cells. This intervention is primarily utilized as a salvage strategy to manage severe or prolonged immune effector cell-associated hematotoxicity (ICAHT), characterized by persistent cytopenias following B-cell maturation antigen (BCMA)-directed CAR T-cell therapy or bispecific antibody therapy in patients with relapsed/refractory multiple myeloma. The reinfused cells migrate to the bone marrow to promote multilineage hematopoietic recovery, effectively restoring counts of neutrophils, platelets, and red blood cells. This procedure is supported by guidelines from the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
- Other names
- autologous CD34+ stem cell infusionCD34 selected stem cell boostCD-34 selected stem cell boostCD 34 selected stem cell booststem cell boostautologous hematopoietic stem cell boost
Beyond the preview
Go deeper on autologous CD34+ stem cell boost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD34+ stem cell boost.